Effect of MUC5b Genetic Polymorphism on Response to Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986020 in a Phase 2 Clinical Trial in Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Minnich, A. [1 ]
Yang, M. [1 ]
Du, S. [1 ]
Soule, B. [1 ]
Luo, Y. [1 ]
机构：
[1] Bristol Myers Squibb, Princeton, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7127
引用
收藏
页数：1
相关论文
共 18 条
  • [1] Evaluation of Collagen Neoepitope Biomarkers in a Phase 2 Trial of BMS-986020, A Lysophosphatidic Acid Receptor Antagonist, for the Treatment of Idiopathic Pulmonary Fibrosis
    Luo, Y.
    Decato, B.
    Palmer, S. M.
    Du, S.
    Charles, E. D.
    Sand, J. M.
    Leeming, D. J.
    Karsdal, M.
    Minnich, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
    Benjamin E. Decato
    Diana Julie Leeming
    Jannie Marie Bülow Sand
    Aryeh Fischer
    Shuyan Du
    Scott M. Palmer
    Morten Karsdal
    Yi Luo
    Anne Minnich
    Respiratory Research, 23
  • [3] LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
    Decato, Benjamin E.
    Leeming, Diana Julie
    Sand, Jannie Marie Bulow
    Fischer, Aryeh
    Du, Shuyan
    Palmer, Scott M.
    Karsdal, Morten
    Luo, Yi
    Minnich, Anne
    RESPIRATORY RESEARCH, 2022, 23 (01)
  • [4] Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
    Gill, Michael W.
    Murphy, Brian J.
    Cheng, Peter T. W.
    Sivaraman, Lakshmi
    Davis, Myrtle
    Lehman-McKeeman, Lois
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2022, 438
  • [5] BMS-986278, an Oral Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist, for Patients With Idiopathic Pulmonary Fibrosis: Results From a Phase 2 Randomized Trial
    Corte, T. J.
    Cottin, V.
    Glassberg, M. K.
    Kreuter, M.
    Ogura, T.
    Suda, T.
    Goldin, J. G.
    Berkowitz, E.
    Elpers, B.
    Kim, S.
    Tirucherai, G. S.
    Watanabe, H.
    Fischer, A.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
    Palmer, Scott M.
    Snyder, Laurie
    Todd, Jamie L.
    Soule, Benjamin
    Christian, Rose
    Anstrom, Kevin
    Luo, Yi
    Gagnon, Robert
    Rosen, Glenn
    CHEST, 2018, 154 (05) : 1061 - 1069
  • [7] Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
    Corte, Tamera J.
    Lancaster, Lisa
    Swigris, Jeffrey J.
    Maher, Toby M.
    Goldin, Jonathan G.
    Palmer, Scott M.
    Suda, Takafumi
    Ogura, Takashi
    Minnich, Anne
    Zhan, Xiaojiang
    Tirucherai, Giridhar S.
    Elpers, Brandon
    Xiao, Hong
    Watanabe, Hideaki
    Smith, R. Adam
    Charles, Edgar D.
    Fischer, Aryeh
    BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)
  • [8] Effects of lysophosphatidic acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a randomized phase 2 trial with BMS-986278
    Maher, Toby M.
    Kaminski, Naftali
    Wang, Fang
    Yarra, Tejaswi
    Elpers, Brandon
    Hu, Sarah
    Schafer, Peter
    Horan, Gerald
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [9] Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
    Cheng, Peter T. W.
    Kaltenbach, Robert F.
    Zhang, Hao
    Shi, Jun
    Tao, Shiwei
    Li, Jun
    Kennedy, Lawrence J.
    Walker, Steven J.
    Shi, Yan
    Wang, Ying
    Dhanusu, Suresh
    Reddigunta, Ramesh
    Kumaravel, Selvakumar
    Jusuf, Sutjano
    Smith, Daniel
    Krishnananthan, Subramaniam
    Li, Jianqing
    Wang, Tao
    Heiry, Rebekah
    Sum, Chi Shing
    Kalinowski, Stephen S.
    Hung, Chen-Pin
    Chu, Ching-Hsuen
    Azzara, Anthony, V
    Ziegler, Milinda
    Burns, Lisa
    Zinker, Bradley A.
    Boehm, Stephanie
    Taylor, Joseph
    Sapuppo, Julia
    Mosure, Kathy
    Everlof, Gerry
    Guarino, Victor
    Zhang, Lisa
    Yang, Yanou
    Ruan, Qian
    Xu, Carrie
    Apedo, Atsu
    Traeger, Sarah C.
    Cvijic, Mary Ellen
    Lentz, Kimberley A.
    Tirucherai, Giridhar
    Sivaraman, Lakshmi
    Robl, Jeffrey
    Ellsworth, Bruce A.
    Rosen, Glenn
    Gordon, David A.
    Soars, Matthew G.
    Gill, Michael
    Murphy, Brian J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (21) : 15549 - 15581
  • [10] BMS-986278, an LPA1 Receptor Antagonist for Idiopathic Pulmonary Fibrosis: Preclinical Assessments of Potential Hepatobiliary Toxicity
    Gill, M. W.
    Lakshmi, S.
    Cheng, P. T. W.
    Murphy, B. J.
    Chadwick, K.
    Lehman-McKeeman, L.
    Graziano, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12